Cancer Family
Malignant Thoracic Neoplasm
CI-CAN-00000256Explore in graph →
2,775 active trials51 approved drugs626 evidence items
- NCIt
- C3576
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000256Explore in graph →
Clinical trials
11,499 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,528)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02995187 | Study of Apatinib as Third-line and Later Therapy in Patients With Small Cell Lung Cancer (SCLC) | unknown | Phase 2 | 25 | Chinese Academy of Medical SciencesOTHER | 1 | Sep 7, 2017 | clinicaltrials |
| NCT02423590 | Study of Gemcitabine/Carboplatin First-line Chemotherapy +/- Apatorsen in Advanced Squamous Cell Lung Cancers | unknown | Phase 2 | 140 | Queen Mary University of LondonOTHER | 1 | Aug 22, 2017 | clinicaltrials |
| NCT02515435 | The Efficacy and Safety of Apatinib in Heavily Pretreated Advanced Non-squamous Non-small Cell Lung Cancer | unknown | Phase 2 | 40 | Tongji UniversityOTHER | 1 | Aug 18, 2017 | clinicaltrials |
| NCT03065764 | 89Zr-labeled Pembrolizumab in Patients With Non-small-cell Lung Cancer | unknown | Phase 2 | 10 | Amsterdam UMC, location VUmcOTHER | 1 | Aug 17, 2017 | clinicaltrials |
| NCT03219762 | Study of Nab-paclitaxel in Sensitive and Refractory Relapsed SCLC(Nabster) | unknown | Phase 2 | 65 | Gruppo Oncologico Italiano di Ricerca ClinicaOTHER | 1 | Jul 26, 2017 | clinicaltrials |
| NCT03205930 | Neo-MASCT Immunotherapy for Advanced NSCLC. | unknown | Phase 1 / Phase 2 | 20 | The First People's Hospital of LianyungangOTHER | 1 | Jul 5, 2017 | clinicaltrials |
| NCT03153358 | Icotinib Combined With SBRT for Patients With Metastatic Non-squamous NSCLC With EGFR Mutation | unknown | Phase 2 | 60 | Sichuan Cancer Hospital and Research InstituteOTHER | 0 | May 16, 2017 | clinicaltrials |
| NCT01963195 | Evaluation of the High Dose of Icotinib in Advanced Lung Cancer Patients After Failure of Target Therapy | unknown | Phase 2 | 30 | Anhui Medical UniversityOTHER | 1 | May 8, 2017 | clinicaltrials |
| NCT03123445 | Endostar First-line Treatment of Advanced NSCLC | unknown | Phase 2 | 150 | China Medical University, ChinaOTHER | 0 | Apr 21, 2017 | clinicaltrials |
| NCT03123484 | β-elemene Combine With EGFR-TKI for Advanced EGFR-TKI-resistant NSCLC | unknown | Phase 2 | 80 | China Medical University, ChinaOTHER | 0 | Apr 21, 2017 | clinicaltrials |
| NCT02844114 | Clinical Study of Ganoderma Lucidum Spore Combined With Chemotherapy(LCKY2015-21(x)) | unknown | Phase 2 | 60 | Gao YajieOTHER | 1 | Mar 31, 2017 | clinicaltrials |
| NCT02714608 | A Study of Ginsenoside H Dripping Pills for Advanced Non-Small Cell Lung Cancer (NSCLC) | unknown | Phase 2 | 144 | Tasly Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 21, 2017 | clinicaltrials |
| NCT03074864 | Targeted Treatment With Intercalated Radiotherapy in EGFR-mutant IIIA/IIIB NSCLC(TREND) | unknown | Phase 2 / Phase 3 | 90 | Guangdong Provincial People's HospitalOTHER | 1 | Mar 9, 2017 | clinicaltrials |
| NCT01869023 | Phase II Study of Six Hours Low Dose Gemcitabine Plus Cisplatin in the Treatment for Advanced Pleural Mesothelioma | unknown | Phase 2 | 26 | Instituto Nacional de Cancerologia de MexicoOTHER | 1 | Mar 3, 2017 | clinicaltrials |
| NCT01980472 | Chemotherapy Plus Bevacizumab in Elderly Non-small Cell Lung Cancer Patients | unknown | Phase 2 | 50 | Grupo de Investigación y Divulgación OncológicaOTHER | 1 | Feb 27, 2017 | clinicaltrials |
| NCT02974933 | Apatinib Mesylate Combined With Pemetrexed in the Treatment of Pretreated Advanced Non-squamous Non-small Cell Lung Cancer | unknown | Phase 2 | 48 | Wuling OuOTHER | 1 | Feb 17, 2017 | clinicaltrials |
| NCT03053856 | Adjuvant Pembrolizumab in N2 Positive Non-small Cell Lung Cancer Patients | unknown | Phase 2 | 37 | Samsung Medical CenterOTHER | 1 | Feb 15, 2017 | clinicaltrials |
| NCT03050437 | A Study Comparing Pemetrexed Plus Cisplatin Versus Pemetrexed Alone in NSCLC Patients Who Have Progressed on First Line EGFR-TKI | unknown | Phase 2 | 96 | Samsung Medical CenterOTHER | 1 | Feb 10, 2017 | clinicaltrials |
| NCT03047525 | Study of DC-CTL Combined With CIK for Advanced Solid Tumor | unknown | Phase 1 / Phase 2 | 200 | Xiaoyi HuangOTHER | 1 | Feb 9, 2017 | clinicaltrials |
| NCT01714908 | Phase II Study of Erlotinib With Concurrent Radiotherapy in Unresectable NSCLC With Activating Mutation of EGFR in Exon 19 or 21(RECEL) | unknown | Phase 2 | 100 | Jinming YuOTHER | 1 | Feb 7, 2017 | clinicaltrials |
| NCT01744925 | Icotinib at Different Doses in Second-line Treatment for Non-small Cell Lung Cancer Patients With Wild Type EGFR | unknown | Phase 2 | 60 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 7, 2017 | clinicaltrials |
| NCT02370017 | Combined Effect of Natural Killer Cell and Doublet Chemotherapy in Advanced NSCLC as the 1st Line Treatment(ANKL-2) | unknown | Phase 2 | 68 | The Catholic University of KoreaOTHER | 1 | Feb 3, 2017 | clinicaltrials |
| NCT03002844 | EGFR-TKI With/Without Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism | unknown | Phase 2 | 50 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 0 | Dec 28, 2016 | clinicaltrials |
| NCT02029209 | To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in the Phase II/III Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer | unknown | Phase 2 / Phase 3 | 110 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Dec 16, 2016 | clinicaltrials |
| NCT02839954 | CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor | unknown | Phase 1 / Phase 2 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 6, 2016 | clinicaltrials |
| NCT02587689 | Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor | unknown | Phase 1 / Phase 2 | 20 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 5, 2016 | clinicaltrials |
| NCT02980809 | Topotecan Plus Apatinib Versus Topotecan Alone as Second-line Therapy in Small-cell Lung Cancer | unknown | Phase 2 | 60 | First Hospitals affiliated to the China PLA General HospitalOTHER_GOV | 0 | Dec 2, 2016 | clinicaltrials |
| NCT02975609 | Phase II Trial of SBRT Compared With Conventional Radiotherapy for Oligometastatic Non-Small Cell Lung Cancer | unknown | Phase 2 | 100 | Shanghai Chest HospitalOTHER | 1 | Nov 29, 2016 | clinicaltrials |
| NCT02787447 | Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI Therapy | unknown | Phase 2 | 46 | First People's Hospital of HangzhouOTHER | 1 | Nov 25, 2016 | clinicaltrials |
| NCT02787473 | A Study of Pemetrexed Plus Cisplatin With Concurrent Radiation Therapy Followed by Docetaxel Consolidation in Patients With Inoperable Squamous Cell Lung Cancer | unknown | Phase 2 | 54 | First People's Hospital of HangzhouOTHER | 1 | Nov 25, 2016 | clinicaltrials |
| NCT02274337 | Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of AC0010 in Advanced Non Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 100 | Sun Yat-sen UniversityOTHER | 1 | Nov 23, 2016 | clinicaltrials |
| NCT02972320 | Extensive Stage Sclc Patients Who Were Benefit From First-line Treatment Accept Temozolomide Maintain Therapeutic | unknown | Phase 2 | 60 | Yunpeng LiuOTHER | 1 | Nov 23, 2016 | clinicaltrials |
| NCT02755675 | uPAR-PET for Prognostication in Patients With Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma and Large Cell Neuroendocrine Carcinoma of the Lung | unknown | Phase 2 | 120 | Rigshospitalet, DenmarkOTHER | 1 | Nov 21, 2016 | clinicaltrials |
| NCT02960607 | High-dose Icotinib Treatment Beyond Progression in EGFR Mutant NSCLC | unknown | Phase 2 | 25 | Chinese Academy of Medical SciencesOTHER | 1 | Nov 18, 2016 | clinicaltrials |
| NCT02961270 | Icotinib in Non-small Cell Lung Cancer Patients With Uncommon EGFR Mutation | unknown | Phase 2 | 30 | Chinese Academy of Medical SciencesOTHER | 1 | Nov 11, 2016 | clinicaltrials |
| NCT02951637 | Chemotherapy Plus Gefitinib for Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomized Controlled Trial | unknown | Phase 2 | 300 | Shanghai Chest HospitalOTHER | 0 | Nov 1, 2016 | clinicaltrials |
| NCT02943798 | Optimization for the Treatment of Advanced Pulmonary Large Cell Neuroendocrine Carcinoma | unknown | Phase 2 | 118 | Shanghai Chest HospitalOTHER | 0 | Oct 25, 2016 | clinicaltrials |
| NCT01683175 | Erlotinib in Post Radical Operation NSCLC Patients With EGFR Mutation | unknown | Phase 2 | 94 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Oct 20, 2016 | clinicaltrials |
| NCT02930954 | Gefitinib Combined With Chemotherapy or Antiangiogensis in Patients With Bim Deletion or Low EGFR Mutation Abundance | unknown | Phase 2 | 180 | Caicun ZhouOTHER | 1 | Oct 13, 2016 | clinicaltrials |
| NCT02906384 | Memory and MRI Changes With Hippocampus Avoidance Prophylactic Cranial Irradiation(HA-PCI) for Small Cell Lung Cancer(SCLC) | unknown | Phase 2 | 154 | Zhejiang Cancer HospitalOTHER | 1 | Oct 10, 2016 | clinicaltrials |
| NCT02873416 | Precision Cell Immunotherapy Combined With Chemotherapy in Advanced Lung Cancer | unknown | Phase 1 / Phase 2 | 40 | Ningbo Cancer HospitalINDUSTRY | 1 | Oct 7, 2016 | clinicaltrials |
| NCT01771289 | Neoadjuvant Concurrent Chemoradiation With Weekly Docetaxel/Cisplatin for Resectable IIIA-N2 NSCLC | unknown | Phase 2 | 50 | Peking University People's HospitalOTHER | 1 | Sep 27, 2016 | clinicaltrials |
| NCT02906150 | Thymosin Alpha 1 Plus Maintenance Therapy With the Standard of Care (SoC) in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC), EGFR Wild Type | unknown | Phase 2 | 140 | SciClone PharmaceuticalsINDUSTRY | 1 | Sep 19, 2016 | clinicaltrials |
| NCT02906163 | First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy | unknown | Phase 1 / Phase 2 | 188 | SciClone PharmaceuticalsINDUSTRY | 1 | Sep 19, 2016 | clinicaltrials |
| NCT02862587 | Precision Cell Immunotherapy Combined With TACE in Advanced Liver Cancer | unknown | Phase 1 / Phase 2 | 40 | Shanghai International Medical CenterINDUSTRY | 1 | Sep 2, 2016 | clinicaltrials |
| NCT02886897 | A Study of Combinations of D-CIK Immunotherapy And Anti-PD-1 In Refractory Solid Tumors | unknown | Phase 1 / Phase 2 | 50 | Sun Yat-sen UniversityOTHER | 1 | Sep 1, 2016 | clinicaltrials |
| NCT02802540 | Nabilone Effect on the Attenuation of Anorexia, Nutritional Status and Quality of Life in Lung Cancer Patients | unknown | Phase 2 / Phase 3 | 78 | Instituto Nacional de Cancerologia de MexicoOTHER | 1 | Aug 31, 2016 | clinicaltrials |
| NCT01576796 | Radiotherapy Dose Complement in the Treatment of Hypoxic Lesions Patients With Stage III Non-small-cell Lung Cancer(RTEP-5) | unknown | Phase 2 | 75 | Centre Henri BecquerelOTHER | 1 | Jul 28, 2016 | clinicaltrials |
| NCT02841228 | Intensity-modulated Radiotherapy (IMRT) With Simultaneous Integrated Boost (SIB) for Inoperable Non-small-cell Lung Cancer | unknown | Phase 2 | 40 | Hunan Province Tumor HospitalOTHER | 1 | Jul 22, 2016 | clinicaltrials |
| NCT00697333 | Radiotherapy Planning Based on Positron Emission Tomography With Fluoro-deoxyglucose For Advanced NSCLC(PET-Plan) | unknown | Phase 2 | 200 | Arbeitsgemeinschaft Nuklearmedizin und Strahlentherapie der DEGRO und DGNOTHER | 1 | Jul 14, 2016 | clinicaltrials |
Data updated 23 days agoSource updated Sep 7, 2017source: clinicaltrials